Development and application of the technologies for manipulationg hematopoietic stem cells using cell-regulatory genes
Development and application of the technologies for manipulationg hematopoietic stem cells using cell-regulatory genes
批准号:
11557075
负责人:
OZAWA Keiya
金额:
$7.36万
依托单位:
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (B).
财政年份:
1999
资助国家:
日本
项目状态:
已结题
起止时间:
1999 至 2000
中文摘要
点击翻译按钮获取中文摘要
英文摘要
1) For ex vivo hematopoietic stem cell (HSC) expansion, the transient block of differentiation would be required during the ex vivo culture and we utilized a dominant negative form of the retinoic acid receptor α (RARE). The 32D cells transduced with a retroviral vector containing the RARE gene flanked by the loxP sites at the both ends remained immature and continued to proliferate without showing differentiation even in the presence of G-CSF.When the 32D cells expressing the RARE gene were further transduced with the Cre recombinase gene, the cells differentiated into granulocytes in the presence of G-CSF, indicating that the differentiation block was abolished. The reversible integration of the RARE gene using the Cre/loxP system may be applicable to ex vivo HSC expansion.2) To overcome the low efficiency of gene transfer into HSCs, we have developed a novel strategy for selective expansion of transduced hematopoietic cells. This system involves "selective amplifier genes (SAGs)" which encode fusion proteins between cytokine receptors and the steroid receptor hormone-binding domains (HBDs). The prototype SAG encoded a fusion molecule (GCRER) between the granulocyte colony-stimulating factor receptor (GCR) and the estrogen-binding domain (ER). We have evaluated the SAG system using primary murine bone marrow cells in vivo. The SAG-transduced bone marrow cells were transplanted into lethally irradiated mice, and the reconstituted animals were challenged with Tm. The results suggested that SAG conferred a steroid-responsive growth ability on the transduced hematopoietic cells in vivo, and that selective expansion of these cells is feasible.
期刊论文(132)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
Ogasawara,Y.: "Potential application of dominant negative retinoic acid receptor genes for ex vivo expansion of hematopoietic stem cells."Gene Ther.Mol.Biol.. 3. 293-300 (1999)
小笠原 Y.:“显性失活视黄酸受体基因在造血干细胞离体扩增中的潜在应用。”Gene Ther.Mol.Biol.. 3. 293-300 (1999)
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
Kume,A.: "Green fluorescent protein as a selectable marker of retrovirally transduced hematopoietic progenitors."Stem Cells. 17. 226-232 (1999)
Kume,A.:“绿色荧光蛋白作为逆转录病毒转导的造血祖细胞的选择标记。”干细胞。
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
Kume,A.: "A G-CSF receptor-gyrase B fusion gene : a new type of molecular switch for expansion of genetically modified hematopoietic cells."Biochem.Biophys.Res.Commun.. 260. 9-12 (1999)
Kume,A.:“G-CSF 受体-促旋酶 B 融合基因:用于扩增转基因造血细胞的新型分子开关。”Biochem.Biophys.Res.Commun.. 260. 9-12 (1999)
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
Maeda, Y., Ikeda, U., Oya, K., Shimpo, M., Ueno, S., Okada, K., Saito, T., Mano, H., Ozawa, K., and Shimada, K.: "Endogenously generated nitric oxide by nitric-oxide synthase gene transfer inhibits cellular proliferation."J.Phamacol.Exp.Therapeut.. 292. 3
前田 Y.、池田 U.、大谷 K.、新浦 M.、上野 S.、冈田 K.、斋藤 T.、真野 H.、小泽 K. 和岛田 K.
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
Matsuda, K.M., Kume, A., Ueda, Y., Urabe, M., Hasegawa, M., and Ozawa, K.: "Development of a modified selective amplifier gene for hematopoietic stem cell gene therapy."Gene Ther. 6. 1038-1044 (1999)
Matsuda, K.M.、Kume, A.、Ueda, Y.、Urabe, M.、Hasekawa, M. 和 Ozawa, K.:“用于造血干细胞基因治疗的改良选择性放大器基因的开发。”Gene Ther。
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
共 54 条
Development of a site-specific gene insertion technology for regenerative medicine:Basic study using developmental engineering
-
批准号:23659493
-
项目类别:Grant-in-Aid for Challenging Exploratory Research
-
资助金额:$2.33万
-
财政年份:2011
-
负责人:OZAWA Keiya
-
依托单位:
Development of gene therapy using bone-marrow-derived mesenchymal stem cells
-
批准号:21390296
-
项目类别:Grant-in-Aid for Scientific Research (B)
-
资助金额:$11.4万
-
财政年份:2009
-
负责人:OZAWA Keiya
-
依托单位:
Development of gene therapy for malignant lymphoma using mesenchymal stem cells with tumor-accumulating capacity
-
批准号:19390267
-
项目类别:Grant-in-Aid for Scientific Research (B)
-
资助金额:$11.73万
-
财政年份:2007
-
负责人:OZAWA Keiya
-
依托单位:
Development of AAV (adeno-associated virus) vectors and their application to cancer therapy
-
批准号:17016067
-
项目类别:Grant-in-Aid for Scientific Research on Priority Areas
-
资助金额:$42.88万
-
财政年份:2005
-
负责人:OZAWA Keiya
-
依托单位:
DEDIFFERENTIATION OF NON-HEMATOPOIETIC TISSUE BY GENETIC MANIPULATION AND ITS ACQUISITION OF PLASTICITY AND HEMATOPOIETIC TRANSDIFFERENTIATION
-
批准号:16390281
-
项目类别:Grant-in-Aid for Scientific Research (B)
-
资助金额:$7.68万
-
财政年份:2004
-
负责人:OZAWA Keiya
-
依托单位:
Development of the gene therapy technologies using adeno-associated virus (AAV)
-
批准号:12470203
-
项目类别:Grant-in-Aid for Scientific Research (B)
-
资助金额:$9.34万
-
财政年份:2000
-
负责人:OZAWA Keiya
-
依托单位:
Development of the method for chromosomal site-specific integration of transgenes using AAV and its application to hematopoietic cells
-
批准号:10470213
-
项目类别:Grant-in-Aid for Scientific Research (B)
-
资助金额:$6.59万
-
财政年份:1998
-
负责人:OZAWA Keiya
-
依托单位:
Development of a novel regulatory gene for in vivo & in vitro expansion of transduced hematopoietic stem cellss
-
批准号:09557087
-
项目类别:Grant-in-Aid for Scientific Research (B)
-
资助金额:$5.57万
-
财政年份:1997
-
负责人:OZAWA Keiya
-
依托单位:
Development of a novel gene therapy technology for site-specific integration of large-sized genes
-
批准号:08457280
-
项目类别:Grant-in-Aid for Scientific Research (B)
-
资助金额:$4.54万
-
财政年份:1996
-
负责人:OZAWA Keiya
-
依托单位:
Molecular study of hematopoiesis-supporting ability of C3H10T1/2 mouse embryo fibroblasts
-
批准号:06454345
-
项目类别:Grant-in-Aid for General Scientific Research (B)
-
资助金额:$3.58万
-
财政年份:1994
-
负责人:OZAWA Keiya
-
依托单位:
海外基金